Bolt Biotherapeutics, Inc.
Clinical trials sponsored by Bolt Biotherapeutics, Inc., explained in plain language.
Develops immuno-oncology therapies using antibody-drug conjugates and immune-stimulating payloads.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug BDC-4182 targets stomach cancer by waking up the immune system Results expected May 2027 (estimated)